# Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

> **NCT06995001** · PHASE1 · COMPLETED · sponsor: **Guangdong Hengrui Pharmaceutical Co., Ltd** · enrollment: 35 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** SHR-2173
- **DRUG:** SHR-2173 ；Placebo
- **DRUG:** SHR-2173 ；Placebo
- **DRUG:** SHR-2173 ；Placebo
- **DRUG:** SHR-2173 ；Placebo

## Key facts

- **NCT ID:** NCT06995001
- **Lead sponsor:** Guangdong Hengrui Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-28
- **Primary completion:** 2024-11-28
- **Final completion:** 2024-11-28
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06995001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06995001, "Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06995001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*